TrialJournal of cancer research and clinical oncology2021

Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046.

Slavomir Krajnak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.